CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Jun 27, 2024 8:30am EDT

CytoDyn to Host Webcast to Provide Company Update

May 28, 2024 8:30am EDT

May 2024 Letter to Shareholders

May 16, 2024 8:30am EDT

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 29, 2024 8:30am EST

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Feb 01, 2024 8:30am EST

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Jan 29, 2024 8:30am EST

CytoDyn Announces Webcast to Provide Company Update

Dec 07, 2023 4:00pm EST

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

Nov 21, 2023 8:30am EST

November 2023 Letter to Shareholders

Nov 03, 2023 4:02pm EDT

CytoDyn Announces Company Updates and Investment Community Update Webcast

Jul 11, 2023 4:05pm EDT